This page has been generated automatically. To view the article in its original context, you may follow the link below:
https://www.medrxiv.org/content/10.1101/2025.01.02.25319875v1
Furthermore, if you wish to have this article removed from our website, please reach out to us.
Abstract
Introduction
Non-communicable illnesses are the primary causes of early death worldwide. Disease susceptibility is influenced by both genetic factors and environmental conditions. Biobanks have enhanced our knowledge of genetic determinants of such diseases, yet the impact of environmental factors is projected to be greater. Individuals also shape their own environments and lifestyles based on genetically driven preferences, resulting in gene-environment interactions that necessitate large datasets for investigation. Biobanks may not possess adequate lifestyle and environmental information, which restricts their application for research aimed at disease prevention. We introduce a protocol for a biobank-recall study (BioRecall) to gather lifestyle and environmental exposures and integrate these with genotypes, biological samples, and clinical outcomes. Participants from the Central Finland Biobank diagnosed with type 2 diabetes will be invited to take part in the pilot study.
Methods and analysis
All previously genotyped participants of the Central Finland Biobank, who have been diagnosed with type 2 diabetes and consented to recalls, will be asked to fill out an electronic survey on the MyBiobank portal. Based on the initial feasibility assessment, there are 1,386 eligible candidates. The survey includes validated queries regarding present and historical lifestyles, anthropometric measurements, weight loss history, health conditions, symptoms, job characteristics, emotional status, and living environment. Zip code data will facilitate the addition of spatial environmental information. Genotype and relevant clinical data will be provided to the study in accordance with the Finnish Biobank Act and will be combined with the survey data.
Ethics and open data
The Human Sciences Ethics Committee of the University of Jyvaskyla has provided a positive review of the study protocol (1671/13.00.04.00/2023). The Central Finland Biobank has sanctioned the research plan (no: BB24-0333-A01). The data collected will be returned to the Central Finland Biobank for research purposes with the consent of participants. Authorization for data utilization can later be requested through standard protocols of the Fingenious service (www.fingenious.fi). If successful, the study will be broadened to include other donors and Finnish biobanks.
Competing Interest Statement
The authors have asserted there are no competing interests.
Funding Statement
This initiative is supported by the JYU.Well strategic funding obtained from the University of Jyvaskyla (to ES) and the research infrastructure funding awarded by the Research Council of Finland (grant number: 358894 to ES) as part of the BBMRI.fi consortium. ES is funded by the Research Council of Finland (grant numbers: 341750, 346509, and 361981), Juho Vainio Foundation, and Paivikki and Sakari Sohlberg Foundation. SR and TF are financed by the Juho Vainio Foundation. MR is supported by the Research Council of Finland (grant number: 330185). KA receives partial support from the European Regional Development Fund through the Regional Council of Northern Savo (No. A80407) for the advancement of FOODNUTRI infrastructure and by the Joint Action on Cardiovascular Diseases and Diabetes (JACARDI), funded by the EU4Health Programme (Grant Agreement No. 101126953).
Author Declarations
I affirm that all pertinent ethical standards have been adhered to, and all required IRB and/or ethics committee approvals have been acquired.
Yes
The specifics of the IRB/oversight entity that granted approval or exemption for the research discussed are provided below:
The Human Sciences Ethics Committee of the University of Jyvaskyla has issued a favorable opinion regarding the study protocol (1671/13.00.04.00/2023). Central Finland Biobank has approved the research plan (no: BB24-0333-A01).
I confirm that all necessary patient/participant permissions have been secured and the relevant institutional forms have been archived, ensuring that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients, or participants themselves) outside the research team, thus cannot be used to identify individuals.
Yes
I recognize that all clinical trials and other prospective interventional research must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study referenced in the manuscript has been registered, and the trial registration ID is included (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining the reason for the study’s delayed registration).
Yes
I have adhered to all applicable research reporting guidelines, including any relevant EQUATOR Network research reporting checklist(s) and other relevant materials, if applicable.
Yes
Data Availability
The Finnish biobank data can be accessed via the Fingenious services (managed by the Finnish biobank cooperative). The newly developed physical activity questions from the project, as well as their REDCap implementation, are available from the corresponding authors upon a reasonable request. The HDI questionnaire can be accessed and is administered by the Finnish Institute for Health and Welfare (THL). Feedback developed based on the HDI can be requested from the FOODNUTRI project (KA) upon a reasonable request.
This page has been generated automatically. To view the article in its original context, you may follow the link below:
https://www.medrxiv.org/content/10.1101/2025.01.02.25319875v1
Furthermore, if you wish to have this article removed from our website, please reach out to us.
